Piper Sandler & Co. on Thursday started its coverage of immunodiagnostics specialist Diasorin (DIA.MI) with a neutral rating and a price target of 75 euros.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)